New York, Jan 11, 2026, 16:22 EST — Market closed.
- ISRG ended Friday 0.2% higher at $586.24, hovering near the upper edge of its recent trading range
- Bernstein bumped up its target to $740; Goldman followed suit with an increase, per TipRanks
- Traders are focused on the J.P. Morgan Healthcare Conference and the earnings window opening on Jan. 22
Bernstein bumped up its price target on Intuitive Surgical (ISRG.O) to $740 from $700, maintaining an “Outperform” rating. The robotic surgery firm’s shares closed Friday up 0.2% at $586.24, after trading between $579.62 and $589.58. Its 52-week range stands at $425 to $616. 1
U.S. markets are closed Sunday, yet the schedule keeps moving. J.P. Morgan’s annual Healthcare Conference takes place Jan. 12–15 in San Francisco. Intuitive is set to present at 9:00 a.m. PT on Wednesday. After that event, the next earnings report is expected around Jan. 22, according to analyst forecasts.
The timing is crucial as medtech investors look to recalibrate their 2026 outlook following a tougher year for the sector. Bernstein’s Lee Hambright pointed out that large-cap U.S. medtech stocks climbed 5% in 2025, lagging behind the S&P 500’s 16% gain. His top picks for 2026 include Intuitive, Boston Scientific, and Stryker.
For Intuitive, the conference and earnings primarily serve as a gauge of procedure growth — essentially, how many surgeries are done with its da Vinci systems — and whether hospitals continue investing in new robots or hold off on capital expenditures.
Investors are zeroing in on the recurring revenue segment—covering instruments, accessories for each case, and services linked to the installed base. This mix can shift margins, even if headline system sales remain stable.
Goldman Sachs bumped its price target up to $714 from $621 while maintaining a buy rating, according to TipRanks. Though price targets look further ahead, they frequently influence how strongly the market reacts to management’s remarks at JPM and during earnings calls.
Intuitive’s next-gen da Vinci 5 system secured U.S. FDA 510(k) clearance in 2024. CEO Gary Guthart commented, “We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5.” 2
But the setup works both ways. ISRG is near its recent peaks, so any cautious signals on procedure trends, hospital budgets, or competition in robotic surgery could still weigh heavily on the stock, even if there’s no obvious flaw.
ISRG traders are gearing up for the 9:00 a.m. PT session Wednesday at the J.P. Morgan Healthcare Conference. After that, all eyes turn to the late-January earnings release, which will shine a light on procedure growth and the company’s outlook.
